Table 2.

Summary of in vitro evaluation of compounds 13, 16 and 18.

Compound	R	Kinase inhibition IC50 (μM)		HeLa IC50 (μM)
		EGFR	VEGFR2
13	–	0.10 ± 0.02	0.47 ± 0.09	10 ± 2.1
16	F	6.17 ± 0.22	0.09 ± 0.01	18.5 ± 1.6
18	NO2	0.37 ± 0.01	2.52 ± 0.09	30 ± 1.2
Erlotinib	–	0.10 ± 0.01	0.004 ± 0.11	NT
Sorafenib	–	0.06 ± 0.004	0.005 ± 0.001	NT